Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Genmab - ADR

The U.S. Food and Drug Administration has approved AbbVie Inc and Danish drugmaker Genmab's experimental blood cancer therapy for adult patients who have received at least two prior lines of treatment, the companies said on Friday.

US FDA approves Genmab-AbbVie's blood cancer therapy

NORTH CHICAGO, Ill. , May 19, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLYTM (epcoritamab-bysp), as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B–cell lymphoma (HGBL), after two or more lines of systemic therapies.

EPKINLY™ (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

AbbVie (ABBV) announces the seventh FDA approval of its JAK inhibitor, Rinvoq, for the treatment of adults with moderately to severely active Crohn's disease.

AbbVie's (ABBV) Rinvoq Gets FDA Nod to Treat Crohn's Disease

PNC Financial Services

Phillips 66

U.S. Bancorp

Verizon

I consider companies that combine a relatively high Dividend Yield and Dividend Growth Rate to be particularly attractive for dividend income investors. The reason being that these companies can help you to significantly increase your extra income in the form of dividends from year to year.

5 High Yield Stocks With Steady Dividend Growth And An Attractive Valuation

–  The co-primary endpoints of endoscopic response (visible reduction of intestinal lining damage) and clinical remission were achieved by significantly more patients treated with RINVOQ (upadacitinib) at week 12 and week 52 versus placebo1 –  Clinical response was achieved by significantly more patients treated with RINVOQ (upadacitinib) versus placebo as early as week 2 in induction studies1 –  This indication marks the seventh FDA approval for RINVOQ across gastroenterology, rheumatology and dermatology1 NORTH CHICAGO, Ill. , May 18, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib) for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response or intolerance to one or more TNF blockers.1 This is the seventh FDA approval for RINVOQ across rheumatology, dermatology, and gastroenterology, where it is now indicated in both ulcerative colitis and Crohn's disease.1 Access the multimedia news release here: https://www.multivu.com/players/English/9145751-abbvie-fda-crohns-disease/ "AbbVie recognizes the need for more treatment options for Crohn's disease that can help address both rapid relief of symptoms along with the visible reduction of intestinal lining damage," said Thomas Hudson, M.D.

U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults

Accenture Plc

Automatic Data Processing

Applied Materials

ASML Hld

Best Buy

Blackrock Inc

Cisco Systems

Expeditors International of Washington

Fastenal

Ferguson Enterprises Inc

Garmin

Home Depot

Infosys

KLA-Tencor

Lockheed Martin

Lowe's

Lam Research

Mastercard

Monolithic Power Systems

Merck

Paychex

Rollins

Snap-on

Skyworks Solutions

The 4-factor dividend growth portfolio was launched on November 1st, 2022, and despite weaker performance recently, it finished ahead of the S&P 500 total return at the half-year mark. The portfolio underperformed the S&P 500 Total Return by 397 bps during the month of April.

4-Factor Dividend Growth Portfolio - Half-Year Mark

THE FIRST AND ONLY HYALURONIC ACID INTRADERMAL MICRODROPLET INJECTION, APPROVED FOR IMPROVED SKIN SMOOTHNESS OF THE CHEEKS IRVINE, Calif. , May 15, 2023 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of SKINVIVE™ by JUVÉDERM® to improve skin smoothness of the cheeks in adults over the age of 21.1 SKINVIVE™ by JUVÉDERM® is the first and only hyaluronic acid (HA) intradermal microdroplet injection for skin smoothness available in the U.S. with results lasting through six months with optimal treatment.1 SKINVIVE™ by JUVÉDERM® is a smooth, injectable HA gel that contains a small amount of local anesthetic (lidocaine).1 Unlike other facial injectables that enhance and augment the treatment area, SKINVIVE™ by JUVÉDERM® improves skin quality in the cheeks by smoothing the skin and increasing hydration.

SKINVIVE™ by JUVÉDERM® Receives U.S. FDA Approval

Cardinal Health

Chevron

Realty Income Corp

PepsiCo

Walgreens

It seems almost humorous that bullish Wall Street strategists and even more bullish financial media talking heads continue to tout that a Federal Reserve pause, and perhaps even a rate cut, may soon be in the cards.

Recession and Market Sell-Off Likely Coming Soon: 7 Safe Dividend Aristocrats to Buy Now

Johnson & Johnson

Many investors do not consider Peter Lynch to be a dividend investor – an unfortunate misunderstanding in my view. He has so many valuable insights into dividend stocks. It is just these insights are overshadowed by his success with 10-baggers.

AbbVie Or Johnson & Johnson? Let's Ask Peter Lynch

Anheuser-Busch InBev

Duke Energy

Archer-Daniels-Midland Company

NextEra Energy

Exxon Mobil

While there's nothing quite as exciting as betting everything on a hot growth enterprise, prudent investors may want to consider the best dividend stocks for market crash. In late April, CNBC reported that investors face the threat of persistently higher inflation while simultaneously digesting a bleak economic outlook.

7 Dividend Stocks That Will Pay You Through Any Market Turmoil

AbbVie just reported poor earnings, and there may be regulatory headwinds coming. Despite that, things appear to be going according to management's plan.

1 Relatively Safe Dividend Growth Stock to Buy Hand Over Fist Right Now

As expected, AbbVie's revenue and earnings both dropped in Q1. However, the drug company offers a sizable dividend that is well-covered.

Looking for Steady, Passive Income? Buy AbbVie Stock

-  Oral presentations highlight efficacy and safety outcomes from the upadacitinib (RINVOQ®) clinical trial program in adults with moderately to severely active Crohn's disease, and investigational use of linaclotide (LINZESS®) in treating functional constipation in pediatric patients aged 6 to 17 years  -  Twenty-nine abstracts showcase AbbVie's vast portfolio and continued commitment to changing the way patients living with gastrointestinal disorders manage their condition NORTH CHICAGO, Ill. , May 6, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will present 29 abstracts during the 2023 Digestive Disease Week (DDW) Annual Meeting, May 6-9, 2023, being held in Chicago and virtually.

AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

Pfizer

AbbVie is entering a new era but still offers the same great dividend. Johnson & Johnson is an ideal stock for retirees with its strong dividend and low volatility.

3 Great Income Stocks That Retirees Should Love

Broadcom

Hershey

New Linde PLC

Raytheon Technologies

UnitedHealth Group

Large-cap stocks are those that have a market capitalization above $10 billion and are synonymously known as big cap stocks. Market cap is calculated by multiplying the share price by the number of shares outstanding.

7 Dividend-Paying Large-Cap Stocks to Buy in May

Scotts Miracle-Gro

Are These Cannabis Stocks Good Long-Term Positions? The post Top Ancillary And Medical Marijuana Stocks In May 2023 appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Top Ancillary And Medical Marijuana Stocks In May 2023

AbbVie's sales of two key immunology drugs missed some analysts' estimates -- but plenty of signs point to long-term growth. The company also is excelling in two other growth markets.

2 Things About AbbVie That Investors Are Ignoring

AbbVie dropped almost 8% after its most recent earnings release, which was triggered by lower-than-expected guidance and a sales decline caused by the Humira patent loss. The good news is that the company is seeing strong growth in its non-Humira core business, with accelerating growth expectations in the years ahead.

AbbVie Sells Off, I Am Buying

Toronto-Dominion Bank

AbbVie, Toronto-Dominion Bank, and Verizon Communications all offer yields exceeding 3%. These businesses have strong financials that can enable them to not only continue paying their current dividends but potentially even increase them.

3 of the Best High-Yielding Dividend Stocks to Buy in May

Vertex Pharmaceuticals

AbbVie announced last week that it's shutting down its cystic fibrosis (CF) program. This decision makes Vertex's monopoly in CF even stronger.

Vertex Pharmaceuticals Stock Is an Even Better Buy Now Thanks to AbbVie

AbbVie is facing Humira's loss of exclusivity, but it is working on fixing that problem. The company should earn approval for new products, thereby improving its lineup.

Where Will AbbVie Be in 5 Years?

News for AbbVie Stock (ABBV)